Your browser doesn't support javascript.
Antibody-dependent enhancement and SARS-CoV-2 vaccines and therapies.
Lee, Wen Shi; Wheatley, Adam K; Kent, Stephen J; DeKosky, Brandon J.
  • Lee WS; Department of Microbiology and Immunology, University of Melbourne at the Peter Doherty Institute for Infection and Immunity, Melbourne, Victoria, Australia.
  • Wheatley AK; Department of Microbiology and Immunology, University of Melbourne at the Peter Doherty Institute for Infection and Immunity, Melbourne, Victoria, Australia.
  • Kent SJ; ARC Centre for Excellence in Convergent Bio-Nano Science and Technology, University of Melbourne, Parkville, Victoria, Australia.
  • DeKosky BJ; Department of Microbiology and Immunology, University of Melbourne at the Peter Doherty Institute for Infection and Immunity, Melbourne, Victoria, Australia. skent@unimelb.edu.au.
Nat Microbiol ; 5(10): 1185-1191, 2020 10.
Article in English | MEDLINE | ID: covidwho-752497
ABSTRACT
Antibody-based drugs and vaccines against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) are being expedited through preclinical and clinical development. Data from the study of SARS-CoV and other respiratory viruses suggest that anti-SARS-CoV-2 antibodies could exacerbate COVID-19 through antibody-dependent enhancement (ADE). Previous respiratory syncytial virus and dengue virus vaccine studies revealed human clinical safety risks related to ADE, resulting in failed vaccine trials. Here, we describe key ADE mechanisms and discuss mitigation strategies for SARS-CoV-2 vaccines and therapies in development. We also outline recently published data to evaluate the risks and opportunities for antibody-based protection against SARS-CoV-2.
Subject(s)

Full text: Available Collection: International databases Database: MEDLINE Main subject: Pneumonia, Viral / Viral Vaccines / Coronavirus Infections / Antibody-Dependent Enhancement / Betacoronavirus Type of study: Experimental Studies / Prognostic study Topics: Vaccines Limits: Animals / Humans Language: English Journal: Nat Microbiol Year: 2020 Document Type: Article Affiliation country: S41564-020-00789-5

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Main subject: Pneumonia, Viral / Viral Vaccines / Coronavirus Infections / Antibody-Dependent Enhancement / Betacoronavirus Type of study: Experimental Studies / Prognostic study Topics: Vaccines Limits: Animals / Humans Language: English Journal: Nat Microbiol Year: 2020 Document Type: Article Affiliation country: S41564-020-00789-5